Abstract
Objective: The aim of this study was to investigate the efficacy of favipiravir (FVP) in severe COVID-19.
Materials and methods: This is a retrospective study of 142 COVID-19 patients with severe pneumonia signs, who received inpatient treatment between March 15 and May 20, 2020. The patients were divided into two groups according to the use of FVP treatment; group 1 (n = 99) included patients who treated with FVP and group 2 (n = 43) who didn’t receive FVP.
Results: Mean age was 66.47 ± 11.89 in group 1, and 68.58 ± 14.78 in group 2. Forty patients (40.4%) in group 1 and 22 (51.2%) in group 2 were treated in the intensive care unit (P > 0.05). The proportion of eosinophil, tendency of increasing thrombocyte counts and eosinophil/neutrophil ratio in FVP group was significantly higher than non-FVP group (p < 0.05). In Group 1, patients had significantly reduced erythroid series, and elevated uric acid levels as side effects of FVP. With respect to complications during hospitalization, there was no significant difference among the groups for mechanical ventilator requirement, acute kidney injury, dialysis requirement, and sepsis (P > 0.05). The mortality rates in Group 1 (n = 26 [26.3%]) were lower than those in group 2 (n = 16 [37.2%]), but it was not statistically significant.
Conclusion: While the treatment of COVID-19 pneumonia options was limited during the initial stages of the pandemic, the FVP may be effective in severe cases. To confirm this effect, randomized controlled studies are needed in patients of all disease severities.
References
- References [1] Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054–62. doi: 10.1016/S0140-6736(20)30566-3 [2] Shi Q, Zhang X, Jiang F, Zhang X, Bimu C et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care 2020; 43 (7): 1382-1391. doi: 10.2337/dc20-0598
Abstract
Amaç: Çalışmamızda, şiddetli COVID-19'da favipiravirin (FVP) etkinliğini araştırmak amaçlandı.
Yöntem: 15 Mart - 20 Mayıs 2020 tarihleri arasında yatarak tedavi gören, ağır pnömoni belirtileri olan 142 COVID-19 hastası retrospektif olarak analiz edildi. Hastalar FVP tedavisinin kullanımına göre iki gruba ayrıldı; grup 1 (n = 99) FVP ile tedavi edilen hastaları ve grup 2 FVP tedavisi almayan hastaları içeriyordu.
Bulgular: Grup 1'de ortalama yaş 66,47 ± 11,89, grup 2'de 68,58 ± 14,78 idi. Grup 1'de 40 hasta (% 40,4) ve grup 2'de 22 (% 51,2) yoğun bakım ünitesinde tedavi edildi (P> 0,05) . FVP tedavi grubunda eozinofil düzeyi, trombosit sayısı ve eozinofil / nötrofil oranı FVP tedvisi almayan gruba göre anlamlı olarak yüksek bulundu (p <0.05). Grup 1'de hastalarda FVP'nin yan etkileri olarak eritroid serileri önemli ölçüde azalmış ve ürik asit seviyeleri yükselmiştir. Hastanede yatış sırasındaki komplikasyonlar açısından mekanik ventilatör ihtiyacı, akut böbrek hasarı, diyaliz gereksinimi ve sepsis açısından gruplar arasında anlamlı fark yoktu (P> 0.05). Grup 1'deki mortalite oranları (n = 26 [% 26.3]), grup 2” deki hastalardan (n = 16 [% 37.2]) daha düşüktü, ancak istatistiksel olarak anlamlı değildi.
Sonuç: COVID-19 pnömonisinde tedavi seçenekleri pandeminin ilk aşamalarında sınırlı iken, ciddi vakalarda FVP etkili olabilir. Bu etkiyi doğrulamak için, tüm hastalık şiddetlerindeki hastalarda randomize kontrollü çalışmalara ihtiyaç vardır.
References
- References [1] Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054–62. doi: 10.1016/S0140-6736(20)30566-3 [2] Shi Q, Zhang X, Jiang F, Zhang X, Bimu C et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care 2020; 43 (7): 1382-1391. doi: 10.2337/dc20-0598
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | March 11, 2021 |
| Acceptance Date | January 14, 2021 |
| Published in Issue | Year 2021 |